about
Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.Demographic, Hematologic, and Clinical Features of Myelodysplastic Syndrome Patients: Results from the First Polish Myelodysplastic Syndrome Registry.Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experienceAngiopoietins in haematopoietic stem cell mobilisation in patients with haematological malignanciesNovel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group.Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.Prognostic value of inhibitor of apoptosis protein family expression in patients with acute myeloid leukemia.Cytotoxic effect of cyclosporin A alone and in combination with 2-chlorodeoxyadenosine against P388 murine leukemia in vivo.Hodgkin's type of Richter's syndrome in familial chronic lymphocytic leukemia treated with cladribine and cyclophosphamide.Jagged-1: a new promising factor associated with favorable prognosis in patients with acute myeloid leukemia.VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment.Safety and feasibility of therapeutic platelet depletion with Spectra Optia in a pregnant woman.The Influence of Comprehensive Cardiac Rehabilitation on Heart Rate Variability Indices after CABG is More Effective than after PCI.Blood pressure response to exercise in young athletes aged 10 to 18 years.Circulating endothelial cell kinetics and their potential predictive value during mobilization procedure.The kinetics of hematopoietic niche cytokines and their influence on mobilization efficacy and timing in patients with hematological malignancies.Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experienceAcute lymphoblastic leukemia in adult first manifested as severe aplastic anemia--role of molecular analysis in correct diagnosisMDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemiaInfluence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemiaHuman leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia?Cytotoxic activity of the selected pyridinium salts against murine leukemia L1210Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patientsEvaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemiaPrognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemiaPolymorphism of CD44 influences the efficacy of CD34(+) cells mobilization in patients with hematological malignancies
P50
Q33372516-9117A76B-318B-4DD4-BEFA-BCA5AB287BEEQ33422437-B5C14807-ED95-4BB5-A454-08BC1BF9667FQ34762492-53EC0536-AD15-4CE3-AC55-C66AAE937B94Q35049174-819211E4-0EB3-4310-83C1-D81E649C8DA6Q37823639-75A88466-0870-45A0-B0F9-36FF030A30B0Q39325327-441C75C7-5979-40F4-8776-9CED3538B2F5Q39388915-CB538323-D398-4D92-AF9E-DC933020532EQ41638629-E5FE6E15-5B84-4B18-BD47-9FFA5CF219ACQ44130039-374CB7CC-3BC3-4686-92E2-DFBE1BAFBEF4Q44475819-ADE82727-4E8B-46D0-80EE-8CD577A3EED6Q46137752-D6E34544-A744-4EBF-BF0B-C471388811C8Q47733010-A758F412-F77A-4506-9DA2-F2B450C8C86AQ47800789-EB16853E-D402-415E-BF49-9CCE3CA98ABEQ48182130-49069D4A-32E6-49B0-B1EE-F9D54485107DQ50752392-6D653D0B-F72C-4351-A2F0-1C3DAD8CE7B9Q50986977-4CBEE587-D0BA-481E-B076-C05343F57240Q53008019-E0419D23-0AEC-473B-94E9-25B757E0EAA2Q64048474-D4D8395D-F5A2-4971-87BA-F5B340A05986Q74540329-0E6885C7-9C77-40DD-B24A-C0180E3C1BF3Q79330797-3E0B0679-884B-4B46-9116-49F82C26E814Q80288353-23FA199A-0990-4C93-9D7B-392581C1A1A4Q80292713-DC0C6D0C-62FB-4FEB-8267-E40DF44BD9F5Q80447893-D2A265A5-ED2D-477E-A6DA-C89B68957B99Q82448096-94572915-346C-40A2-BF7D-3185499C4508Q83150953-ED0D2480-E967-45A5-88AF-3F10EECA2981Q84288908-B7CD262B-2B9E-4DE6-BAA4-354C849A0D88Q87554053-9B209CCA-D269-467A-B781-8F46CFBF1563
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-0775-6412
@en
name
Anna Szmigielska-Kaplon
@ast
Anna Szmigielska-Kaplon
@en
Anna Szmigielska-Kaplon
@es
Anna Szmigielska-Kaplon
@nl
type
label
Anna Szmigielska-Kaplon
@ast
Anna Szmigielska-Kaplon
@en
Anna Szmigielska-Kaplon
@es
Anna Szmigielska-Kaplon
@nl
prefLabel
Anna Szmigielska-Kaplon
@ast
Anna Szmigielska-Kaplon
@en
Anna Szmigielska-Kaplon
@es
Anna Szmigielska-Kaplon
@nl
P106
P1153
6603117949
P21
P31
P496
0000-0002-0775-6412